NCT01038674View on ClinicalTrials.gov

Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
InflammationRheumatoid Arthritis
Interventions
DRUG

anti-IL-20

Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.

DRUG

placebo

Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.

Trial Locations (2)

1070

Novo Nordisk Investigational Site, Brussels

PL-02-274

Novo Nordisk Investigational Site, Warsaw

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01038674 - Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter